Literature DB >> 27569451

Risk-stratification management of febrile neutropenia in pediatric hematology-oncology patients: Results of a French nationwide survey.

Mathilde Delebarre1,2, Aude Tiphaine3,4, Alain Martinot3,5, François Dubos3,5.   

Abstract

BACKGROUND: In 2012, new international guidelines for children with chemotherapy-induced febrile neutropenia (FN) were issued, recommending reduced-intensity management strategy based on stratification of infectious risks. Some studies have highlighted practice disparities in different countries and within the same country. Our aim was to assess the current management strategies for the treatment of chemotherapy-induced FN in children in France. PROCEDURE: This survey of all French pediatric oncology-hematology reference centers (n = 30) in late 2012 and early 2013 sent a standardized questionnaire to each center inquiring about their definition of an FN episode, its initial empiric treatment and ongoing management, use of management stratified by risk, and any criteria used for the risk assessment. Each center's management protocol was also analyzed.
RESULTS: All French reference centers participated in this survey, completing 88% of the questionnaire items. Definitions of both fever and neutropenia varied between centers. Ten centers used a risk-stratification strategy for initial management. In all, 42 probabilistic first-line antibiotic treatments were identified. After 48 hr of apyrexia, 17 units applied different forms of step-down therapy.
CONCLUSIONS: Most French centers already offered some form of reduced-intensity or step-down therapy, although they differed substantially in their management of FN episodes. Risk stratification with validated tools is essential to facilitate the implementation of the international recommendations, which would ultimately help to standardize practices in France.
© 2016 Wiley Periodicals, Inc.

Entities:  

Keywords:  cancer; children; febrile neutropenia; management; survey

Mesh:

Substances:

Year:  2016        PMID: 27569451     DOI: 10.1002/pbc.26121

Source DB:  PubMed          Journal:  Pediatr Blood Cancer        ISSN: 1545-5009            Impact factor:   3.167


  6 in total

1.  Trends in bacterial bloodstream infections and resistance in immuno-compromised patients with febrile neutropenia: a retrospective analysis.

Authors:  Coralie Raad; Abdelkader Behdenna; Christine Fuhrmann; Cécile Conter; Daniela Cuzzubbo; Jean-Philippe Rasigade; Yves Bertrand; Carine Domenech
Journal:  Eur J Pediatr       Date:  2021-04-09       Impact factor: 3.183

2.  The influence of different fever definitions on diagnostics and treatment after diagnosis of fever in chemotherapy-induced neutropenia in children with cancer.

Authors:  Stéphanie Wagner; Eva K Brack; Eveline Stutz-Grunder; Philipp Agyeman; Kurt Leibundgut; Oliver Teuffel; Roland A Ammann
Journal:  PLoS One       Date:  2018-02-20       Impact factor: 3.240

3.  Management of children with fever and neutropenia: results of a survey in 51 pediatric cancer centers in Germany, Austria, and Switzerland.

Authors:  Max Scheler; Thomas Lehrnbecher; Andreas H Groll; Ruth Volland; Hans-Jürgen Laws; Roland A Ammann; Philipp Agyeman; Andishe Attarbaschi; Margaux Lux; Arne Simon
Journal:  Infection       Date:  2020-06-10       Impact factor: 3.553

4.  Re-evaluating and recalibrating predictors of bacterial infection in children with cancer and febrile neutropenia.

Authors:  Gabrielle M Haeusler; Robert Phillips; Monica A Slavin; Franz E Babl; Richard De Abreu Lourenco; Francoise Mechinaud; Karin A Thursky
Journal:  EClinicalMedicine       Date:  2020-06-15

5.  Supportive methods for childhood acute lymphoblastic leukemia then and now: A compilation for clinical practice.

Authors:  Alexandra Podpeskar; Roman Crazzolara; Gabriele Kropshofer; Petra Obexer; Evelyn Rabensteiner; Miriam Michel; Christina Salvador
Journal:  Front Pediatr       Date:  2022-09-12       Impact factor: 3.569

6.  Episodes of fever in neutropenia in pediatric patients with cancer in Bern, Switzerland, 1993-2012.

Authors:  Maxime G Zermatten; Christa Koenig; Annina von Allmen; Philipp Agyeman; Roland A Ammann
Journal:  Sci Data       Date:  2019-01-15       Impact factor: 6.444

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.